文献速递腹部技术与安全USMR

超声引导衰减参数(UGAP)技术可在自由呼吸下准确测量肝脂肪变:技术说明

Hepatic steatosis can accurately be measured during free breathing using ultrasound-guided attenuation parameter (UGAP) technology. Technical note.
PubMed 文献 · Eur J Radiol · 2025-12-09

该前瞻性研究纳入健康对照及脂肪变合并纤维化队列,评估UGAP在正常屏气、深吸气、呼气末及自由呼吸四种呼吸时相测量肝脂肪变的诊断效能,以MRI质子密度脂肪分数≥5%为参考标准。结果显示各呼吸时相AUC无显著差异,自由呼吸下测量保持诊断准确性,不能屏气患者可采用UGAP测量。

要点

  • UGAP测量肝脂肪变时,自由呼吸与正常屏气诊断效能无显著差异。
  • 各呼吸时相UGAP均值与正常屏气均值无显著差异。
  • 不能屏气的肝纤维化患者可用UGAP在自由呼吸下完成脂肪变测量。

核心结论

  • 肝纤维化患者若无法屏气,采用UGAP技术可在自由呼吸下测量肝脂肪变并保持诊断准确性。

研究设计与样本

  • 前瞻性研究,2022年9月至2024年10月纳入健康对照及脂肪变合并纤维化队列;组1 N=55采集正常屏气、深吸气、呼气末相,组2 n=37增加自由呼吸相;以MRI质子密度脂肪分数≥5%定义脂肪变(≥S1),以磁共振弹性成像评估纤维化,用AUROC评估诊断效能。

诊断标准与关键数值

  • 肝脂肪变(≥S1)定义为MRI质子密度脂肪分数≥5%;组1(N=55)UGAP诊断脂肪变AUROC:正常屏气0.79(95%CI:0.66-0.92)、深吸气0.78(95%CI:0.64-0.91)、呼气末0.77(95%CI:0.64-0.91);组2(n=37)AUROC:正常屏气0.71(95%CI:0.53-0.89)、深吸气0.66(95%CI:0.47-0.85)、呼气末0.67(95%CI:0.49-0.86)、自由呼吸0.72(95%CI:0.55-0.90)。

临床应用与阅片要点

  • 对不能屏气的肝纤维化患者,可在自由呼吸下用UGAP测量肝脂肪变;组2中正常屏气与各呼吸时相UGAP均值(dB/cm/MHz)无显著差异(n=37,NS)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: Hitherto, breathing phases impact on hepatic steatosis measurements with quantitative ultrasound method in patients with liver fibrosis is not well known. The aim of the study was to evaluate different breathing phases for the ultrasound guided attenuation parameter (UGAP) technology for hepatic steatosis in patients with liver fibrosis.

MATERIAL AND METHODS: Healthy controls and a cohort with steatosis and fibrosis was prospectively enrolled between September 2022 and October 2024. Presence of hepatic steatosis (≥ S1) with UGAP was defined as magnetic resonance imaging ≥ 5 % proton density fat fraction (PDFF), and presence of fibrosis was evaluated with magnetic resonance elastography. In a group with N = 55 measurements were sampled during normal breath hold, peak-inspiration and end-expiration phases. In a group with n = 37 free breathing phase was added during recorded volume sampling for measurements after examination. The diagnostic performance of UGAP for all four breathing methods were evaluated based on area under the receiver operating characteristic curve (AUROC) with PDFF.

RESULTS: In group N = 55 no difference in diagnostic performance was seen between AUC for normal breath hold 0.79 (95 %CI: 0.66-0.92), inspiration 0.78 (95 %CI: 0.64-0.91) and expiration 0.77 (95 %CI: 0.64-0.91). In group n = 37 no difference was seen between AUC for normal breath hold 0.71 (95 %CI: 0.53-0.89), inspiration 0.66 (0.47-0.85), expiration 0.67 (95 %CI: 0.49-0.86) and free breathing 0.72 (95 %CI: 0.55-0.90). No difference between normal breath-hold UGAP mean values dB/cm/MHz and all tested breathing phases mean values (n = 37, NS).

CONCLUSION: Patients with liver fibrosis and inability to hold their breath during measurements for hepatic steatosis can be measured using UGAP technology with sustained diagnostic accuracy.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Byenfeldt M, Nasr P, Lindam A, et al. Hepatic steatosis can accurately be measured during free breathing using ultrasound-guided attenuation parameter (UGAP) technology. Technical note. Eur J Radiol. 2025. PMID: 41391291. doi:10.1016/j.ejrad.2025.112602

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。